GPX4 and breast carcinoma: Among the synthesized compounds, compound 6-Cl-substituted 41 (Ki: 0.24 ± 0.06 μM) exhibited the highest activity in suppressing MDM2-mediated p53 degradation as well as GPX4 levels in MCF-7 breast cancer cells.